Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30883516 | 1.00 | CRBN (0.52) | CRBNDDB1POLBGSPT1ADRB1 | |
| SCHEMBL25029440 | 0.86 | CRBN (0.51) | CRBNDDB1POLB | |
| SCHEMBL27225354 | 0.86 | CRBN (0.51) | CRBNDDB1POLBGSPT1ADRB1 | |
| SCHEMBL30883502 | 0.86 | CRBN (0.51) | CRBNDDB1POLBGSPT1ADRB1 | |
| SCHEMBL30955798 | 0.83 | CRBN (0.53) | CRBNDDB1POLBADRB1 | |
| SCHEMBL31443955 | 0.82 | CRBN (0.47) | CRBNDDB1POLB | |
| SCHEMBL31342253 | 0.82 | CRBN (0.44) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL31443569 | 0.82 | CRBN (0.45) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL30643676 | 0.82 | CRBN (0.44) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL26641269 | 0.82 | CRBN (0.44) | CRBNDDB1POLBGSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024039901-A2 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | CRBN 302/4885DDB1 206/4885POLB 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.